Dilution and Performance Woes for Zogenix
- Zogenix (NASDAQ:ZGNX) has officially priced its announced stock offering at $2.00/unit, each unit consisting of one share of common stock and one warrant to purchase … Continue Reading
Read nowSearch Results for zogenix
GW Pharma’s Disregarded Risks Make Upcoming Conference a Pivotal Catalyst
Insights - GW Pharma (GWPH) announced the submission of its rolling NDA for their cannabidiol candidate Epidiolex, treating rare epilepsy conditions Lennox-Gastaut Syndrome and Dravet Syndrome. At … Continue Reading
Premium
The Weekly Biotech Roundup, Here are Our Latest Trades & Insights
Recap - It was a shortened trading week in the U.S. with markets closed the entirety of Friday and half of Thursday, though activity and volatility in the healthcare … Continue Reading
Read nowWhat’s with Legislators and Drugs this Week? Weekly Recap
Recap - First, W.V. Democratic Senator Joe Manchin introduced a bill last week to overturn the FDA’s marketing approval of Zohydro ER, an opioid pain product developed by Zogenix Inc. (ZGNX) and approved just last … Continue Reading
Read now
It’s Time to Own Durect – Again
Research - With the stock hitting previous support, we think its time to own Durect (DRRX) yet again.
Premium
BioDelivery Data Release Removes An Overhang
Research - BioDelivery Sciences (BDSI) and partner Endo Health Solutions (ENDP) announced on the 23rd that the second of three phase 3 trials testing one of its lead drug candidates, BEMA buprenorphine, … Continue Reading
Read nowDid You See What Happened?
Insights - Of course you did – everyone did. Small-cap drug developer Intercept Pharmaceuticals (ICPT) climbed 540% in two days. Not only that, but the stock gapped up by 200 points on day one, almost … Continue Reading
Read now